This study is a phase IV, open-label, single arm, multicentre study whose aim is to assess whether interferon-free and ribavirin-free Direct Acting Antiviral (DAA) Hepatitis C Virus (HCV) therapy with grazoprevir/elbasvir, will be feasible for the treatment of People who inject drugs (PWID) with recent injecting drug use and chronic HCV genotype 1 or 4 infection.
This study will recruit patients who have been diagnosed with acute (within 26 weeks) infection that are also infected with HIV (HIV/HCV coinfection). The goal of this trial is to find out if the treatment duration can be reduced from 12 weeks to 8 weeks in people who are infected with HCV genotype 1 and 4. A total of 80 patients will be enrolled. The drugs being used in this study are Zepatier (grazoprevir plus elbasvir) combined into one pill taken once-a-day.
This is a nonrandomized (participants may decide which drugs they want to take), multi-site, open-label trial to evaluate a novel two-drug combination regimen (uprifosbuvir (MK-3682) 450 mg + ruzasvir [RZR; MK-8408] 180 mg once daily [q.d.] for 12 weeks) in male and female treatment-naïve (TN taken once-a-day) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.
The trial will enroll people infected with HCV and people coinfected with HIV/HCV to test the effectiveness of Harvoni treatment to improve central nervous system functioning. The study will use MRI and blood tests to measure the changes the brain.
Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
To view the entire clinical trial information, click here